Gastrointestinal Stromal Tumors: Innovation from Diagnosis to Treatment Based on 15 Years of Experience of a Peripheral Hospital in Portugal
Journal Title: Cancer Studies & Molecular Medicine – Open Journal - Year 2017, Vol 3, Issue 1
Abstract
Aim: To investigate fifteen years of experience, in managing GISTs, according to best clinical practice, on a peripheral Portuguese Hospital. Define the behavior of GIST’s and the association between the histological, immunehistochemistry characteristics and disease progression. Question if the optimal treatment was delivered in GIST patients, based on medical evidence, where limitations on evaluating molecular signatures exists. Methods: A retrospective analysis of cases treated in Hospital of Entre Douro and Vouga from 1 January 1999 to 31 December 2014 was performed. Demographic characteristics were evaluated related to tumor characteristics according to the National Institute of Health criteria and disease progression. All patients were evaluated in a multidisciplinary team. An expert treatment decision was made according to the National Institute of Health criteria of Gastrointestinal stromal tumor’s risk of recurrence after surgery. Statistical study was performed using SPSS version. Results: Sixty-three cases were evaluated, 61.9% in female patients and 38.1% male. The median age at diagnosis was 69 years. A progressive increase in the incidence of GISTs was documented since 1999 to 2014. The most common source locations was the stomach with forty-five patients (71.4%), When assessing the Mitotic count, 27% was superior to 5 mitosis/50HPF and 73% was inferior to 5 mitosis /50HPF. Sixty-two patients underwent surgery with R0 resection rate of 94% Immunohistochemistry was performed in all patients, and sixty-one patients were positive for CD117. Only two patients were CD117 negative. No KIT gene mutation analysis was performed. Regarding the biological risk of recurrence or metastasis, according to the National Institute of Health, 25,4 % of the patients had a very high risk, 19,0% had an intermediate risk, 34,9% had a low risk and 20,6 % had a very low risk. Of the 63 patients, 25.4% (n=16) were submitted to adjuvant treatment with imatinib (400 mg/ daily) during 3 years. Only 7.9% (n=5) received palliative treatment with imatinib and sunitinib. Only in 11% of the patients the disease progressed (median time to progression of 36 months). The mortality rate was 12.7% (n=8). Fifty-five patients were alive (87.3%) at the end of this retrospective study. Conclusions: Mutation analysis was not performed, which might have influenced the treatment and prognosis. Optimize therapy based on molecular signatures are extremely important for a cost-effective treatment.
Authors and Affiliations
Joana Espiga de Macedo
Keywords
Related Articles
- EP ID EP551964
- DOI 10.17140/CSMMOJ-3-115
- Views 120
- Downloads 0
Classifying Lung Adenocarcinoma and Squamous Cell Carcinoma using RNA-Seq Data
Background: Lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) are two primary subtypes of non-small cell lung carcinoma (NSCLC). Currently, the most widely used method to discriminate between LUAD and LU...
Rounding Down Chemotherapeutic Agents to the Nearest Vial Size as a Cost Containment Measure
Background: High cancer treatment costs significantly affect health care expenditures. Drug waste reduction of costly drugs can reduce the treatment cost. Methods: A retrospective study conducted at King Abdulaziz Medica...
Application of Radionuclides and Antibody-Drug Conjugates to Target Cancer
Radionuclide therapy and antibody-drug conjugates are used to locate and kill cancer cells by the utilisation of monoclonal antibodies. These bio-vectors are able to transport a cytotoxic drug payload and/or radiation in...
Activation of Inflammatory Responses Correlate With Hedgehog Activation and Precede Expansion of Cancer Stem-Like Cells in an Animal Model of Residual Triple Negative Breast Cancer after Neoadjuvant Chemotherapy
Triple Negative Breast Cancer (TNBC) is characterized as a lack of expression of the hormonal receptors, estrogen and progesterone, and Human epidermal growth factor receptor 2 (HER2) and as such is unresponsive to curre...
Neurofibromatosis Type I and Multiple Gastrointestinal Stromal Tumors: A Unique Identity
Von Recklinghausen’s disease (VRD) is a genetic disorder characterized by the growth of multiple noncancerous tumors of nerves and skin (neurofibromas) and areas of hypo or hyperpigmentation of the skin. It is also known...